Radicava ORS (edaravone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRST NAME:		
Instructions: Please fill out all important for the review (e.g., this form is Protected Health I	chart notes or lab data, to su		est). Information contained in	
			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODI	E:	
PATIENT INSURANCE ID NUM	MBER:			
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES: IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:		,		
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
☐ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERA	PY INITIATED:	
DURATION OF THERAPY (SPE	CIFIC DATES):			

Continued on next page.



Radicava ORS (edaravone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
☐ Amyotrophic Lateral Sclerosis (ALS)☐ Other diagnosis:	ICD-10:		
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A	
Clinical Information:			
Initial Approval: Is this drug being prescribed to this patrial? □ Yes □ No	itient as part of a treatment regimen sp	ecified within a sponsored clinical	
Is prescriber a neurologist? ☐ Yes ☐ N	lo		
Has the patient been diagnosed with criteria? Yes No (documentation	clinically definite or probable ALS based n required)	on El Escorial revised criteria or Awaji	
Is the patient taking any other form of	f edaravone? □ Yes □ No		
If patient is taking another form of ed	aravone, will they discontinue when sta	rting oral edaravone? Yes No	
Has the patient had a diagnosis of ALS	for less than or equal to 2 years? Yes	☐ No (documentation required)	
Is the patient's percent-predicted force (documentation required)	ed vital capacity (%FVC) greater than or	equal to 80%? 🗆 Yes 🗆 No	
-	onality for most activities of daily living n each individual item of the ALS Functionired)	_	
Renewal: Has patient responded to therapy con (documentation required of ALSFRS-R	npared to pretreatment baseline with discore required)?	isease stability or mild progression	
Does patient have a cumulative score required)? Yes No	on the ALSFRS-R of ≤ 3? (documentation	n required of ALSFRS-R score	
Is patient dependent on invasive vent	ilation or tracheostomy? ☐ Yes ☐ No		
Is prescriber a neurologist? □ Yes □ No			
-			



Radicava ORS (edaravone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required		
information is received.		
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that		
the Health Plan, insurer, Medical Group, or its designees may perform a routine audit and request the medical		
information necessary to verify the accuracy of the information	ition reported on this form.	
Prescriber Signature or Electronic I.D. Verification:	Date:	
CONFIDENTIALITY NOTICE: The documents accompanying this transmiss you are not the intended recipient, you are hereby notified that any disc of these documents is strictly prohibited. If you have received this inform	losure, copying, distribution, or action taken in reliance on the contents	
and arrange for the return or destruction of these documents.		

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

